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Abstract:  
Background: 
It is unclear whether liver transplantation confers an increase in health-related quality 
of life (HR-QoL) across all dimensions of health. This study aimed to estimate the 
effect of liver transplantation on HR-QoL. 
 
Methods: 
Pre- and post-transplantation patients attending an outpatient clinic were invited to 
complete the condition-specific ‘Short form of liver disease QOL’ questionnaire. 
Mixed-effect linear regression and propensity-score matching (PSM) on pre-
transplantation characteristics were used to estimate the difference in overall HR-
QoL associated with transplantation.  
 
Results: 
454/609 (74.5%) eligible patients were included in the analysis, 102 (22.5%) pre-
transplantation, and 352 (77.5%) post-transplantation. Overall HR-QoL post-
transplantation significantly increased in patients without hepatocellular carcinoma 
(HCC) (β=16.84, 95% CI: 13.33 to 20.35, p<0.001), but not with HCC (β=1.25, 95% 
CI: -5.09 to 7.60, p=0.704). Donation after circulatory death (DCD) organ recipients 
had a significantly lower HR-QoL (β=-4.61, 95% CI: -8.95 to -0.24, p=0.043). 
Following PSM, transplantation was associated with a significant increase in overall 
HR-QoL (average treatment effect: 6.3,95% CI: 2.1 to 10.9). 
 
Conclusion: 
There is a significant improvement in HR-QoL attributable to transplantation in this 
cohort. Post-transplantation HR-QoL was affected by several factors, including HCC 
status and DCD transplantation, which has important implications for counselling 
prior to liver transplantation.  
Introduction: 
Liver transplantation remains the sole therapeutic intervention with curative potential 
for end-stage liver disease [1]. With sustained improvements in operative technique 
and post-operative management, survival after transplantation has continued to 
improve in recent decades. In the UK in 2014/15, 1 year and 5 year survival was 
reported to be 92.4% and 80.1%, respectively [2]. Liver transplantation has been an 
endeavour primarily focussed on saving life, yet with its success comes an 
increasing need to understand its impact on quality of life [3]. This is particularly 
important in the small number of patients who undergo liver transplantation with the 
primary aim of improving quality of life, for instance, those with intractable itch or 
polycystic liver disease. In the early period after transplantation, quality of life is 
influenced by the surgery itself, any associated complications, and the overall 
trajectory of recovery [4]. In the longer term, quality of life can clearly be affected by 
graft failure, disease recurrence, and the complications of immunosuppressive 
medication, such as infection, malignancy, nephrotoxicity, and cardiovascular 
complications [5].  
 
Patient-centred outcome measures and health-related quality of life (HR-QoL) are 
increasingly being recognised as essential for comprehensive surgical outcome 
evaluation [6, 7]. These can assess the physical, psychological, emotional, and 
social dimensions of health. Several liver transplantation-specific instruments have 
been developed in recent decades [8] and have been used to compare pre- and 
post-transplantation HR-QoL [9-13]. These studies have demonstrated that liver 
transplantation provides an overall benefit to quality of life, however, there remains 
uncertainty around whether this improvement is across all aspects of health. 
Furthermore, questions remain over the relationship between HR-QoL and time from 
transplantation [14, 15], re-transplantation [16, 17], and the use of donation after 
circulatory death (DCD) liver allografts [18-20].  
 
From a patient’s perspective, the post-interventional quality of life can be of greater 
importance than the quantity of life gained [21]. As such, there is a clear mandate to 
provide robust evidence regarding post-transplantation HR-QoL, in addition to 
morbidity and mortality. This would allow patients to make fully informed decisions 
on their healthcare and to evaluate post-operative outcomes more completely. 
Therefore, this study aimed to estimate the effect of liver transplantation on the 
health-related quality of life of patients. 
  
Methods: 
Population: 
Consecutive patients attending the Scottish Liver Transplantation Unit for an 
outpatient clinic or waiting list assessment between 16th July and 3rd September 
2015, and 15th August and 14th September 2017 were invited to take part. This 
enabled an interval cross-sectional assessment of those attending. Patients were 
eligible if over 18 years of age, and not being considered for living liver donation. 
 
Data Collection: 
The validated ‘Short form of liver disease quality of life’ (SF-LDQOL) questionnaire 
[9] was used to assess the condition-specific HR-QoL of eligible patients, after verbal 
consent was obtained. This includes 36 items distributed over 9 domains; symptoms 
of liver disease, effects of liver disease, concentration/memory, health-related 
distress, sexual function, quality of sleep, loneliness, hopelessness, and stigma of 
liver disease. In addition, this provides an overall HR-QoL score. Formal institutional 
ethical approval was not required as this study was considered a service evaluation, 
otherwise involving routinely collected data. 
 
Statistical Analyses: 
Patient characteristics were summarised to compare differences between the two 
groups. Continuous data were summarised as a mean and analysed using the 
appropriate parametric tests. Categorical data were cross-tabulated, and differences 
in proportions were tested using chi-squared (Χ2) or Fisher’s exact tests. Statistical 
analyses were conducted in R v3.3.1 (R Foundation for Statistical Computing). The 
threshold of statistical significance was set at p<0.05 a priori. 
 
All questionnaire responses were assigned a value based upon the original Likert 
scale [9], and summated into a mean score for each domain (scaled to a value out of 
100). All domains were equally weighted before being summated into a mean overall 
score. 
 
Mixed-effect linear regression model 
Differences in overall HR-QoL were adjusted using a mixed-effect linear regression 
model. Variables used as fixed effects included: age (years); sex (male, female); 
ethnicity (white, non-white); blood group (O or non-O); body mass index (BMI); pre-
transplantation Model of End Stage Liver Disease (MELD) category (<10, 10-15, 15-
20, >20); primary liver disease (alcoholic, cholestatic, non-alcoholic fatty liver 
disease (NAFLD), viral (hepatitis B or C), or other aetiology); and hepatocellular 
carcinoma (HCC) status (present, absent). These are routinely collected in patients 
assessed for transplantation at UK Liver Transplant Units and could plausibly affect 
HR-QoL or time to transplant. First-order interactions were checked and included in 
the model if found to be influential, with final model selection performed through 
minimisation of the Akaike information criterion. Repeat questionnaires from the 
same individual who had attended during both periods were modelled as a random-
effect. A subgroup analysis was conducted on post-transplantation patients to 
describe the association with organ type (donation after brain death (DBD) or 
donation after circulatory death (DCD) organ), number of transplantations received 
(first transplantation or re-transplantation), and time since transplantation (years). All 
effect estimates were presented as beta-coefficients, alongside the corresponding 
95% confidence interval. 
 
  
Propensity-score matching  
Propensity-score matching (PSM) was used to minimise selection bias and balance 
variables between pre- and post-transplantation groups. The propensity score was 
defined as the probability that a patient would be assigned to a particular group (pre- 
or post-transplantation) depending on the observed characteristics for an individual 
[22]. Pre-transplantation patients were matched with post-transplantation patients 
based on the same fixed variables as in the mixed-effect linear regression model. 
Patients without complete data for all matching variables were excluded from the 
analysis, and the remainder were assigned to pre- or post- groups and matched 
according to their propensity score. 
 
Full propensity-score matching [23, 24] was used, and this subclassification method 
matches one or more controls to each treated patient. A weighting is applied to each 
control patient to minimise the average of the estimated distance measure (log odds 
of being transplanted) between the treated patient and the controls. The weightings 
for the control patients sum to one and are incorporated as a weighted-regression. 
This allows more control patients to contribute to the model compared with a simpler 
“greedy” matching algorithm, such as nearest-neighbour. Patients who appear as a 
case and a control (e.g. patients with repeated questionnaires who received a 
transplant in the interim) were not included in the matching procedure, but were 
simply included one-to-one, together with a random-effect assignment to account for 
the fact they are the same patient. The balance in factors between groups was 
assessed before and after matching via the absolute standardised mean difference 
[22]. A value < 0.2 was considered to indicate a covariate was well balanced 
between treatment groups, however differences were not tested [25]. 
 The overall average treatment effect (ATE) is defined as the estimated average 
effect on the HR-QoL of the whole sample being transplanted (e.g. equivalent to the 
quantity of interest in a randomised control trial) [22], not just those who were 
transplanted. This summary measure of treatment effect is an average of the 
average treatment effect on treated (ATT) and average treatment effect on controls 
(ATC), and was chosen to reflect that patients who undergo transplant are not the 
same as the population on the waiting list. The ATT was determined through use of 
known predictors of quality of life in a regression in the propensity-score matched 
dataset using pre-transplantation (control) patients alone. We then simulate 
expected values for quality of life metrics using these coefficients in the post-
transplantation (treated) patients alone. This gives us an estimate of the 
counterfactual – what would the quality of life be in the treated patients had they not 
undergone transplantation. We then compare the observed quality of life in the 
transplant patients and compare this with the expected quality of life to give a robust 
ATT. The converse was performed to derive the ATC in the cohort.  Models were 
adjusted using multivariate logistic regression to account for any residual imbalance 
(minimised using the full matching approach) and to improve the robustness in 
calculation of the measures of treatment effect [26].  
Results: 
Patient Characteristics: 
There were 609 patients eligible for inclusion over both study periods (Figure 1). Of 
these, 488 (80.1%) completed the questionnaire, and response rates were similar 
across period 1 (81.8%, n=306), and period 2 (77.4%, n=182). Overall, 74 (12.2%) 
refused participation, and 47 (7.7%) were not encountered. Patients were 
subsequently excluded based on questionnaire incompleteness (n=16, 2.6%) or 
missing matching variable data (n=18, 3.0%). Therefore, 454 patients (74.5%) were 
included in the final analyses, with 102 respondents (22.5%) being pre-
transplantation, and 352 (77.5%) being post-transplantation (Table 1). Fifty-three 
patients had repeated questionnaires – 11 had received a transplantation since 2015 
, with others continuing to be pre-transplantation (n=1) or post-transplantation 
(n=41). Within the sample, the most common primary liver diseases were alcoholic 
(24.0%), cholestatic (22.5%), viral (14.8%) and cholestatic liver disease (11.2%). A 
description of primary liver diseases included within the “other” category is provided 
in supplementary table 1.  
 
Average follow-up time of post-transplantation patients was 4.3 years (sd = 5.0), with 
114 (32.4%) under 1 year, 132 (37.5%) 1 to 5 years, and 106 (30.1%) over 5 years 
since transplantation. 
 
Mixed-effects linear regression: 
The overall unadjusted HR-QoL score was 13.3 (95% CI: 9.6 to 17.1, p<0.001) 
points higher in the post-transplantation group compared with the pre-transplantation 
group. There was a significant 1st order interaction between transplantation and HCC 
status on overall HR-QoL (p<0.001), and so this was included as a composite 
variable in the mixed-effect linear regression model (Table 1). There was a persistent 
increase in overall HR-QoL associated with transplantation in non-HCC patients after 
adjustment (β = 16.84, 95% CI: 13.33 to 20.35, p<0.001). However, there was no 
significant difference in HR-QoL associated with transplantation in patients with HCC 
(β = 1.25, 95% CI: -5.09 to 7.60, p=0.704). Subgroups within the post-transplantation 
group were also compared (Table 1). Following adjustment, receipt of a DCD-organ 
was associated with a significantly lower post-transplantation HR-QoL (β = -4.61, 
95% CI: -8.95 to -0.24, p=0.043) compared with receipt of a DBD-organ. In contrast, 
the overall HR-QoL remained consistent over time for post-transplantation patients, 
and on re-transplantation.  
 
Propensity-score matching: 
Balance Diagnostics: 
The baseline characteristics of pre- and post-transplantation respondents were 
explored before and after propensity-score matching (Table 2). In the unmatched, 
there was a higher proportion of males, higher mean BMI, different distribution of 
primary liver diseases, and lower MELD score in pre-transplantation patients. 
However, following propensity-score matching, there was a substantial improvement 
in the balance of most variables, with standard mean difference (SMD) ≤ 0.2 for all 
variables. 
 
The level of missingness in the questionnaire responses was <1% for all variables 
included in the analysis, with the exception of the effect of liver disease on 
housework (20%) or travel (18%), effect of medications (16%), and libido (10%). 
Three questions (9a, 9b, 10) related to sexual function were excluded due to levels 
of missingness >20%. 
 
 
Results: 
In the unmatched sample, pre-transplantation patients rated the health-related 
distress domain significantly lower, and the perceptions of loneliness significantly 
higher than the overall score (Table 3; Figure 2). However, following PSM and 
multivariable adjustment, no substantial differences were observed. Similarly, post-
transplantation patients rated quality of sleep significantly lower, and social stigma 
and loneliness significantly higher than the overall score (Table 3; Figure 2). 
However, this persisted following matching and multivariable adjustment in all cases 
except loneliness. The Average Treatment Effect on the overall score was estimated 
to be 6.3 (95% CI: 2.1 to 10.9). The ATE for each questionnaire domain was also 
investigated (Table 3; Figure 3), with significant improvements in HR-QoL 
attributable to transplantation across all domains bar cognition which did not 
demonstrate a significant change in this cohort (ATE: 3.3, 95% CI: -0.6 to 7.4). Other 
measures of treatment effects, including the average treatment effect on the treated 
(ATT) and the average treatment effect on the control (ATC), are presented in 
Supplementary Table 2. 
 
 
  
Discussion: 
With continuing improvements in patient and graft survival post-transplantation in 
recent years, the definition of success in liver transplantation has increasingly 
focussed on the long-term quality of life for patients. This study aimed to estimate the 
effect of liver transplantation on the HR-QoL of patients. To the best of our 
knowledge, it represents one of the largest quality of life studies in liver  
transplantation patients conducted to date [3]. This is the first study to utilise 
propensity-score matching to answer this question, which allowed causal inference 
of the effect of liver transplantation on quality of life within the context of an 
observational study. As observed in previous studies on the topic [9, 14, 27], these 
results show a significant improvement in overall self-reported health in post-
transplantation patients (ATE: 6.3, 95% CI: 2.1 to 10.9). This is the first time the 
change in quality of life attributable to liver transplantation has been quantified in this 
manner. This study also describes the association between quality of life and a 
variety of pre- and post-transplantation factors which represent important 
considerations in counselling of pre-transplantation patients.  
 
While there is evidence to support an overall improvement in HR-QoL after 
transplantation in general [3, 14, 27, 28], there continues to be uncertainty whether 
this is across all aspects of health. The heterogeneity of instruments utilised in the 
literature to assess HR-QoL in liver transplantation patients has been a factor, given 
the challenges in directly comparing these results. Nevertheless, the physical 
aspects of health in liver transplantation patients appear to show consistent 
improvement across studies [3, 14, 27, 28]. Changes in symptoms such as pain 
have been reported to remain non-significant in some cases [27], whereas there was 
a significant improvement observed in the symptoms domain of the SF-LDQOL in 
this sample (ATE: 6.3, 95% CI 1.4 to 11.4).  
 
In contrast, the evidence for improvement in psychosocial health is less conclusive 
with some reports of no change [27-29] or slight improvement [3, 14] in various 
domains being assessed. Nevertheless, psychosocial function has still been reported 
to be satisfactory in long-term follow up studies [14]. Our results indicate there were 
significant improvements in most aspects psychosocial health assessed. However, 
cognitive function was not found to demonstrate a significant change in this cohort 
attributable to transplantation (ATE: 3.3, 95% CI: -0.6 to 7.4). Pre-transplantation 
counselling process should reflect this, as well as potential disparities in 
improvements (particularly in quality of sleep, loneliness, and social stigma), and that 
statistically significant improvements may not reflect clinical improvement from a 
patient perspective. Sexual function is also known to be a potential issue pre- and 
post-transplantation for both men and women [30]. While there is some evidence to 
support improvement after transplantation, this is not conclusive and may be 
influenced by a reluctance to discuss the topic openly [3]. This was observed within 
this cohort, with three items being excluded due to levels of missingness >20%. 
Therefore, while these results supported an overall improvement in sexual function, 
this does not represent a comprehensive assessment of this aspect of health and 
may be subject to volunteer bias. Overall, more research is required to further 
understand the determinants of each health domain and identify specific avenues for 
improvement. 
 
Quality of life following transplantation is multifactorial and has the potential to be 
influenced by recipient-, donor-, and organ-related factors, as well as the time-point 
at which it is measured. In the mixed-effects linear regression model, transplantation 
in non-HCC patients was associated with a significant increase in overall HR-QoL, 
but with no change in patients with HCC (Table 1). This may be expected given that 
pre-transplantation patients with HCC have a significantly higher overall HR-QoL 
than pre-transplantation patients without HCC. Moreover, no significant difference in 
HR-QoL between HCC and non-HCC groups are seen following transplantation. 
These results make intuitive sense: many pre-transplantation patients with HCC do 
not have established liver failure and may have minimal or no physical symptoms. 
The impact of the diagnosis of cancer on psychosocial wellbeing is well described 
and may also influence HR-QoL in HCC patients. While the full impact a diagnosis of 
HCC has on the HR-QoL in these patients may not have been captured, it is 
important to highlight in counselling that they may not experience a significant 
improvement in terms of liver disease-specific HR-QoL. In contrast, within the mixed-
effects model (Table 2) there were no significant differences in overall HR-QoL 
observed between the different aetiologies of primary liver disease. While patients 
with end-stage liver disease undoubtedly have lower HR-QoL than those without, 
these results remain consistent with the current balance of evidence [14, 31-34]. 
 
There were no significant differences observed between the re-transplantation status 
and time since transplantation post-transplantation subgroups in regard to overall 
quality of life (Table 1). While perhaps contrary to expectations, these results are 
reflected in other studies which indicate that the overall HR-QoL after adjustment 
tends to remain stable over time after the first year post-transplantation [13-16, 35], 
and that re-transplantation does not appear to significantly affect long-term QOL [15, 
17]. In contrast, patients who received a DCD-organ were estimated to have a 
significantly worse HR-QoL (β=--4.61, 95% CI: -8.95 to -0.24, p=0.043) compared to 
those who received a DBD organ. This is consistent with other work on this topic [18, 
19], and may reflect the increased risk of morbidity in DCD organ recipients [36-38]. 
However, it should be noted there is some evidence to suggest that clinical 
outcomes can be equivalent with appropriate patient selection [39, 40], and a recent 
study of long-term DCD-recipients has demonstrated no difference in HR-QoL 
between these groups [41]. While the finding of a lower HR-QoL in DCD-organ 
recipients has important implications for advising patients being offered these 
organs,  it should be emphasised that this does not negate the benefits of higher 
quality-adjusted life years gained from accepting a DCD transplantation [20].  
 
Although widely used, generic HR-QoL instruments (such as SF-36) often fail to 
capture important physical, psychological, emotional, and/or social aspects which 
may affect the quality of life of pre-transplantation patients, such as social stigma 
[42]. While there have been several different instruments developed to assess HR-
QoL liver transplantation patients, there remains no gold-standard [8, 14]. The 
psychometric properties of the SF-LDQOL questionnaire have been evaluated 
previously [9], and it was selected for its disease-specific aspects, correlation with 
SF-36, and clinical utility. An excellent initial response rate (80%) was obtained, 
which compares favourably to other HR-QoL studies in this population [13, 14, 19, 
43], therefore volunteer and selection biases were minimised. However, due to the 
cross-sectional nature of this study there are several factors that may have 
influenced the HR-QoL results observed. Frequent clinic attendees were more likely 
to have been encountered, and so may have had worse HR-QoL due to higher 
MELD scores; shorter post-operative periods; or higher rates and/or severities of 
complications. In contrast, those with the worst HR-QoL may have died or been (re-) 
transplanted which introduces the risk of survival bias and overestimation of HR-QoL 
in the cohort.  
 
This was a single-centre study, and so it is important to recognise the impact of 
patient experience and non-health related factors can have on patient-reported 
outcome measures [44]. As these could differ between the transplantation units, the 
results reported may not reflect the experiences of patients in other areas. In ideal 
circumstances, these concerns could be addressed through a prospective, multi-
centre longitudinal study in which a liver disease-specific questionnaire is 
administered to patients both pre- and post-transplantation. The ultimate aim should 
be to embed quality of life assessment within routine practice in transplantation, 
which would be in line with the drive towards more patient-centred healthcare in the 
NHS [44, 45]. Moreover, this could provide valuable clinical information given there is 
evidence to suggest that quality of life can be predictive of survival [46, 47] and 
hospitalisation [48] in pre-transplantation patients. 
 
One of the primary advantages of using a propensity-score matched analysis in this 
study is that the waiting listing process for transplantation is inherently selective. 
Therefore, comparing the change in quality of life in those who have been 
transplanted alone cannot provide an unbiased assessment of the effect of liver 
transplantation. Furthermore, while propensity-score matching is not, and should not 
be, a substitute for randomised controlled trials, its use can allow causal inference in 
the context of observational research where a trial is not possible.  However, unlike 
randomisation, it does not account for unobserved covariates which might affect 
quality of life, such as those related to pre-transplantation (e.g. duration on the 
waiting list, pre-existent mental health disorders) or post-transplantation status (e.g. 
immunosuppressive medications, chronic graft failure) [3]. Nevertheless, without the 
option to randomise patients to receipt of a liver transplantation (due to pragmatic 
and ethical considerations), propensity-score matching provides the best method of 
causal inference regarding the effect of transplantation upon HR-QoL. Finally, there 
is also no comparison made to healthy controls to determine whether HR-QoL also 
returns to "baseline”, and previous work suggests that quality of life does remain 
lower than the general population [27, 49, 50]. Therefore, patient counselling must 
continue to ensure expectations regarding post-transplantation health remain 
realistic [49]. 
 
Conclusion: 
In conclusion, there is a significant improvement in health-related quality of life in 
patients undergoing liver transplantation. This was also observed across all quality of 
life domains, bar cognitive function. However, patients with HCC did not exhibit a 
significant increase in overall HR-QoL associated with transplantation. Furthermore, 
the quality of life observed in post-transplantation patients remained consistent 
according re-transplantation status, and time since transplantation. In contrast, 
patients who received a DCD-organ were estimated to have a significantly lower HR-
QoL compared to those who received a DBD organ. These findings may assist in 
counselling pre-transplantation patients on their expected quality of life post-
transplantation. However, more research is required to further understand the 
determinants of each health domain and identify avenues for further improvement.  
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